共 19 条
- [1] BENYON R C, IREDALE J P., Is liver fibrosis reversible?, Gut, 46, 4, pp. 443-446, (2000)
- [2] DAS S K, VASUDEVAN D M., Genesis of hepatic fibrosis and its biochemical markers, Scandinavian Journal of Clinical and Laboratory Investigation, 68, 4, pp. 260-269, (2008)
- [3] WALTON K L, JOHNSON K E, HARRISON C A., Targeting TGF-β mediated SMAD signaling for the prevention of fibrosis, Frontiers in Pharmacology, 8, (2017)
- [4] HEMMANN S, GRAF J, RODERFELD M, Et al., Expression of MMPs and TIMPs in liver fibrosis: a systematic review with special emphasis on anti-fibrotic strategies, Journal of Hepatology, 46, 5, pp. 955-975, (2007)
- [5] FAN X, ZHANG Q, LI S, Et al., Attenuation of CCl<sub>4</sub>-induced hepatic fibrosis in mice by vaccinating against TGF-β1, PLoS ONE, 8, 12, (2013)
- [6] MIYAZAWA K, SHINOZAKI M, HARA T, Et al., Two major Smad pathways in TGF-β superfamily signalling, Genes to Cells, 7, 12, pp. 1191-1204, (2002)
- [7] LI Y G, JI D F, ZHONG S, Et al., 1-Deoxynojirimycin inhibits glucose absorption and accelerates glucose metabolism in streptozotocininduced diabetic mice, Scientific Reports, 3, (2013)
- [8] KOJIMA Y, KIMURA T, NAKAGAWA K, Et al., Effects of mulberry leaf extract rich in 1-deoxynojirimycin on blood lipid profiles in humans, Journal of Clinical Biochemistry and Nutrition, 47, 2, pp. 155-161, (2010)
- [9] ROEB E., Matrix metalloproteinases and liver fibrosis (translational aspects), Matrix Biology, 68, pp. 463-473, (2018)
- [10] REDALE J P, THOMPSON A, HENDERSON N C., Extracellular matrix degradation in liver fibrosis: biochemistry and regulation, Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1832, 7, pp. 876-883, (2013)